Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aea57db10fe6e572d4a54808447081e9 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate |
2011-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78bb439a56b5f33fa59937a2feeff67e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_734ba50b6c64194fe8ffcd7bff95e6cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58ba84fba4862ed40748f80da68b399b |
publicationDate |
2013-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2011289234-A1 |
titleOfInvention |
Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
abstract |
Compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist; and a pharmaceutically acceptable carrier are disclosed herein. The conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation. |
priorityDate |
2010-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |